Indian Pharmas To Fall Short Of Export Forecasts
This article was originally published in PharmAsia News
India's pharmaceutical business is expected to miss 2007-2008 export growth forecasts by 23 percent. The industry blames the appreciation of the rupee for the projected failure to reach the 30 percent growth forecast. Also cited for the fall-off were pricing pressures and loss of patent protection in the United States. Others cite a U.S. recession that forces foreign companies to offer greater discounts. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?